CClinicalTrials.gg
Not yet recruitingNCT07562308DEX LMAUpdated May 12, 2026

Laryngeal Mask Airways Are Supraglottic Devices Used to Maintain Airway Patency During Anesthesia and in Difficult Airways. IV Dexmedetomidine Improves LMA Insertion Success and Decreases Coughing, While IV Lidocaine Decreases Postoperative Cough.

An interventional study of Dexamedomedine and Lidocaine (drug) in Pediatric, Elective and Surgery in Early Childhood, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 2 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
2 Years to 12 Years
Sex
All
01

Study summary

Laryngeal Mask Airways Are Supraglottic Devices Used to Maintain Airway Patency During Anesthesia and in Difficult Airways. LMA may help in reducing postoperative pulmonary complications. IV Dexmedetomidine Improves LMA Insertion Success and Decreases trials number, While IV Lidocaine Decreases Postoperative Cough. This is a randomized interventional trial comparing both drugs. IV DEX will be compared vs IV lidocaine regarding the feasibility of insertion, number of trials, incidence of cough, postoperative pulmonary complications and hemodynamic profile.

02

Conditions studied

  • Pediatric
  • Elective
  • Surgery in Early Childhood

Keywords

  • Dexmedetomidine, Lidocaine, LMA, Pediatrics, Elective
03

In context

Lead sponsor

Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Parental/guardian consent.
  • Age 2-12 years
  • ASA physical status I-II.
  • Elective surgery requiring LMA (duration \<2 hours).

Exclusion criteria

Exclusion Criteria:

  • Known airway anomalies (e.g., tonsillar hypertrophy, cleft palate).
  • Cardiovascular disease (bradycardia, arrhythmias).
  • Allergy to study drugs.
  • BMI >95th percentile.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Group (D) DEX

    Dose: 0.2 mcg/kg IV in 10 mL saline, infused over 10 min pre-induction.

    Drug: Dexamedomedine

  • Active comparator
    Group (L) Lidocaine

    Dose: 1.5 mg/kg IV (max 100 mg) in 10 ml saline over 1 min before induction.

    Drug: Lidocaine (drug)

Interventions

  • DrugDexamedomedine

    IV 0.2 mic/ kg of dexmedetomidine will be diluted over 10 ml saline and given to the patient over 10 minutes before induction and assess the feasibility of classic LMA insertion

    Also known as: DEX, Precedex

  • DrugLidocaine (drug)

    IV 1.5 mg/kg of lidocaine will be diluted over 10 ml saline and given to the patient 1 minute before induction and assess the feasibility of classic LMA insertion

06

What researchers measure

Primary outcomes

  1. First-attempt insertion success rate

    The success of the first trial of classic LMA insertion will be assessed. Binary: yes or no.

    Time frame: After induction of anesthesia

Secondary outcomes

  1. Ease of insertion (4-point scale)

    Grade 1: No resistance. Grade 2: Mild resistance. Grade 3: Moderate resistance. Grade 4: Failed insertion and need for another airway management tool.

    Time frame: After Induction of anesthesia

  2. Heart rate

    Monitored continuously and recorded every 15 minutes. Atropine IV will be given if bradycardia occurs.

    Time frame: Every 15 minutes till recovery

  3. MAP

    Mean arterial blood pressure

    Time frame: Every 15 minutes

  4. Recovery Time

    Time from discontinuation of anesthesia till the child is fully awake.

    Time frame: After cessation of anesthesia administration

  5. Postoperative Agitation

    PAED scale 1. The child makes eye contact with the caregiver 2. The child's actions are purposeful 3. The child is aware of his/her surroundings 4. The child is restless 5. The child is inconsolable

    Time frame: In PACU

  6. Postoperative Complications

    Laryngeal Spasm, Coughing

    Time frame: 0,1,2,6 hours postoperative.

  7. PONV

    PONV grade Patient response 0 Without PONV I Nausea without vomiting II Nausea with vomiting (\< 3 times/d) III Vomiting ≥ 3 times/d

    Time frame: 24 hours postoperative

  8. Postoperative sore throat (0-3 scale).

    0 (none) 1. (mild/complaint only upon asking) 2. (moderate/complaint on own) 3. (severe/hoarseness or throat pain).

    Time frame: 24 hours postoperative

07

Study locations

1 site
  • Faculty of Medicine Assiut University
    Asyut, Asyut Governorate 71621, Egypt
08

References and documents

Publications

  • Li L, Zhang Z, Yao Z, Wang H, Wang H, An H, Yao J. The impact of laryngeal mask versus other airways on perioperative respiratory adverse events in children: A systematic review and meta-analysis of randomized controlled trials. Int J Surg. 2019 Apr;64:40-48. doi: 10.1016/j.ijsu.2019.02.020. Epub 2019 Mar 13. PubMed 30878762 ↗
  • Ju Q, Xiao Z, Sun W, Zhu M, Lv P. The anesthesia induction effect of dexmedetomidine in patients undergoing laryngeal mask intubation: a systematic review and meta-analysis of 7 RCTs. Ann Palliat Med. 2021 Dec;10(12):12358-12366. doi: 10.21037/apm-21-2971. PubMed 35016404 ↗
  • Gharaei B, Jafari A, Poor Zamany M, Kamranmanesh M, Aghamohammadi H, Roodneshin F, Teymourian H, Khazaie Y, Dadkhah P. Topical Versus Intravenous Lidocaine in Children With Upper Respiratory Infection Undergoing Anesthesia: A Randomized, Double Blind, Clinical Trial. Anesth Pain Med. 2015 Aug 22;5(4):e23501. doi: 10.5812/aapm.23501v2. eCollection 2015 Aug. PubMed 26473098 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07562308
Lead sponsor
Assiut University
Responsible party
Abdelrahman Hamdy Mohammed (Lecturer of Anesthesia & ICU, Faculty of Medicine, Assiut University, Assiut University) — Principal investigator
First posted
May 1, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Aug 1, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
May 12, 2026

Study contacts

Abdelrahman Hamdy, Lecturer
Contact
abdelrahmanhm89@gmail.com
+201060989574
Mohammed Adel, Lecturer
Contact
01050727722 ext. +2
Abdelrahman Hamdy
principal investigator · Asyut University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion